HC Wainwright Issues Positive Forecast for NextCure Earnings

NextCure, Inc. (NASDAQ:NXTC) – Analysts at HC Wainwright raised their Q3 2026 EPS estimates for NextCure in a research note issued on Wednesday, August 12th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($0.90) for the quarter, up from their prior estimate of ($2.00). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for NextCure’s current full-year earnings is ($7.99) per share. HC Wainwright also issued estimates for NextCure’s Q4 2026 earnings at ($0.79) EPS, FY2027 earnings at ($1.38) EPS, FY2028 earnings at ($1.22) EPS, FY2029 earnings at ($0.75) EPS and FY2030 earnings at $0.12 EPS.

Other equities research analysts also recently issued research reports about the company. Zacks Research upgraded NextCure from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 11th. Weiss Ratings upgraded NextCure from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday. Finally, Wall Street Zen cut NextCure from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $19.00.

NextCure Stock Performance

NXTC stock opened at $8.28 on Friday. The stock has a fifty day moving average of $3.69 and a 200-day moving average of $8.24. NextCure has a fifty-two week low of $1.55 and a fifty-two week high of $15.74. The company has a market capitalization of $29.89 million, a price-to-earnings ratio of -0.95 and a beta of 1.27.

NextCure (NASDAQ:NXTC) last released its quarterly earnings results on Thursday, August 6th. The company reported ($2.80) EPS for the quarter, missing analysts’ consensus estimates of ($1.95) by ($0.85).

Insider Activity

In other NextCure news, major shareholder Adar1 Capital Management, Llc purchased 292,850 shares of the stock in a transaction on Thursday, July 30th. The stock was acquired at an average price of $4.93 per share, with a total value of $1,443,750.50. Following the transaction, the insider directly owned 686,116 shares of the company’s stock, valued at approximately $3,382,551.88. This trade represents a 74.47% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have purchased a total of 346,761 shares of company stock valued at $1,710,807 in the last quarter. 11.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On NextCure

A number of hedge funds have recently added to or reduced their stakes in NXTC. Geode Capital Management LLC increased its position in NextCure by 18.6% during the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock valued at $329,000 after acquiring an additional 3,636 shares during the last quarter. Renaissance Technologies LLC raised its position in NextCure by 18.7% in the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after purchasing an additional 5,300 shares during the period. Marshall Wace LLP bought a new stake in NextCure in the fourth quarter worth about $160,000. Millennium Management LLC purchased a new position in shares of NextCure during the fourth quarter valued at approximately $185,000. Finally, Affinity Asset Advisors LLC grew its stake in shares of NextCure by 28.9% during the fourth quarter. Affinity Asset Advisors LLC now owns 247,294 shares of the company’s stock valued at $3,509,000 after buying an additional 55,412 shares during the last quarter. 42.65% of the stock is currently owned by hedge funds and other institutional investors.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.